Chinese Newcomers Look For Niche Immuno-Oncology Opportunities
Cervical Cancer, SCLC Eyed
Executive Summary
Chinese pharma companies are continuing to pile into the already overcrowded domestic anti-PD-1/L1 sector in China, but despite the competition and regulatory tightening, the latecomers are looking for opportunities in areas such as cervical and small cell lung cancer with relatively fewer contenders.
You may also be interested in...
China Approves World’s First Bispecific IO Drug Amid PD-1/L1 Glut
Akeso’s PD-1/CTLA-4-targeting therapy cadonilimab has been the front-runner in the bispecific antibody field in China, leading about 50 other similar agents under development by domestic pharma firms. With a new conditional approval, it has also gained a head start over home-grown PD-1/L1 antibody rivals in the cervical cancer space.
China’s Top Regulator Upholds Tough Stance Against 'Redundant' Clinical Trials
China's Center for Drug Evaluation has issued fresh warnings that it will tighten reviews of anti-tumor drugs on the grounds that “redundant” development activities waste clinical resources.
Allorion Rides Unconventional Discovery Platforms To Major Funding
Allorion's key innovative attractions include discovery platforms for allosteric inhibitor screening and the discovery of synthetic lethality targets/molecules, along with a small but growing pipeline of novel assets. Founded in 2020, the China- and US-based biotech has now raised more than $100m in three financing deals, including a $50m series B.